10-Q/A: Avid Bioservices Restates Q1 2024 Financials Due to Debt Classification Error

Avid Bioservices has restated its first quarter 2024 financials due to an error in classifying its 2026 convertible notes as long-term debt instead of a current liability.

Summary

• Avid Bioservices has filed an amended quarterly report to restate its unaudited condensed consolidated financial statements for the period ended July 31, 2023.
• The restatement was triggered by an acceleration notice from a holder of its 1.250% Exchangeable Senior Notes due 2026, which revealed an error in classifying the notes as long-term liabilities.
• The company's interest expense for the three months ended July 31, 2023, was also understated due to the failure to reflect additional interest.
• The restatement resulted in an increase in current liabilities and a decrease in stockholders' equity on the balance sheet.
• The company reported a net loss of $2.122 million for the quarter, compared to a net income of $1.361 million in the same period last year.
• Revenue for the quarter was $37.726 million, a slight increase from $36.692 million in the prior year.
• The company's gross profit decreased to $4.1 million from $9.117 million in the same period last year, primarily due to increased costs related to capacity and technology expansions.
• The company's backlog was approximately $189 million as of July 31, 2023.

Sentiment

Score: 4

Explanation: The document reveals significant issues including a restatement due to a material error, a net loss, decreased gross profit, and a material weakness in internal controls. While there is some revenue growth and a positive backlog, the negative aspects outweigh the positives, resulting in a low sentiment score.

Positives

• Revenue increased slightly by 3% year-over-year to $37.726 million.
• The company has a backlog of approximately $189 million, indicating future revenue potential.
• The cell and gene therapy facility is expected to be online by the end of the third quarter of calendar 2023, expanding the company's service offerings.
• The company has taken steps to remediate the material weakness in internal controls.

Negatives

• The company restated its financials due to a material error in debt classification.
• The company reported a net loss of $2.122 million for the quarter, a significant decrease from the net income of $1.361 million in the same period last year.
• Gross profit decreased by $5.017 million year-over-year, primarily due to increased costs and a terminated project.
• The company identified a material weakness in its internal control over financial reporting related to debt accounting.
• The company's disclosure controls and procedures were deemed ineffective as of July 31, 2023.

Risks

• The company's ability to raise additional capital is dependent on market conditions and may not be available on acceptable terms.
• The company's backlog is subject to risks such as customer cancellations, delays, and supply chain issues.
• The company's gross profit is expected to be impacted in the near-term due to increased fixed costs.
• The company's internal controls over financial reporting were deemed ineffective due to a material weakness.

Future Outlook

The company anticipates that its existing cash and cash equivalents, along with anticipated cash flows from operations, will be sufficient to fund operations for at least the next 12 months. The company also expects its cell and gene therapy facility to be online by the end of the third quarter of calendar 2023.

Industry Context

The company operates in the contract development and manufacturing organization (CDMO) industry, which is experiencing growth due to the increasing demand for biologics manufacturing. The company's expansion into cell and gene therapy aligns with the growing market for these therapies.

Comparison to Industry Standards

• The company's gross margin of 11% for the quarter is below the industry average for CDMOs, which typically ranges from 20% to 40%.
• The decrease in gross margin is attributed to increased costs related to capacity and technology expansions, which is a common challenge for CDMOs investing in growth.
• The company's revenue growth of 3% is modest compared to some of its peers in the CDMO industry, which have seen double-digit growth rates.
• The company's backlog of $189 million is a positive indicator of future revenue, but it is important to note that backlog can be subject to cancellations and delays.
• Comparable companies in the CDMO space include Lonza, Catalent, and Samsung Biologics, which have larger scale operations and more diversified service offerings.

Stakeholder Impact

• Shareholders will be negatively impacted by the restatement, net loss, and decreased gross profit.
• Employees may be affected by the company's financial performance and any potential cost-cutting measures.
• Customers may be concerned about the company's financial stability and its ability to deliver on contracts.
• Creditors may be concerned about the company's debt levels and its ability to repay its obligations.

Next Steps

• The company will continue to advance the build-out of CGMP manufacturing suites in its cell and gene therapy facility.
• The company will focus on remediating the material weakness in its internal control over financial reporting.
• The company will monitor its backlog and work to convert it into revenue.

Key Dates

Keywords

restatement, convertible notes, debt classification, financial statements, CDMO, manufacturing, revenue, net loss, internal controls, material weakness